NewAmsterdam Pharma (NASDAQ:NAMS) Director James N. Topper Purchases 1,135 Shares

NewAmsterdam Pharma (NASDAQ:NAMS) Director James N. Topper purchased 1,135 shares of NewAmsterdam Pharma stock in a transaction that occurred on Wednesday, March 26th. The shares were bought at an average price of $22.49 per share, for a total transaction of $25,526.15. Following the transaction, the director now directly owns 3,013,569 shares of the company’s stock, valued at $67,775,166.81. This trade represents a 0.04 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

NewAmsterdam Pharma Stock Performance

Shares of NewAmsterdam Pharma stock opened at $21.76 on Friday. The company has a 50-day simple moving average of $21.66 and a two-hundred day simple moving average of $21.23. The stock has a market capitalization of $2.39 billion, a PE ratio of -8.37 and a beta of -0.04. NewAmsterdam Pharma has a 52-week low of $15.19 and a 52-week high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The company had revenue of $12.77 million during the quarter, compared to analyst estimates of $3.30 million. As a group, equities research analysts forecast that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.

Institutional Investors Weigh In On NewAmsterdam Pharma

Several institutional investors have recently modified their holdings of the business. GF Fund Management CO. LTD. purchased a new position in NewAmsterdam Pharma in the 4th quarter worth about $50,000. National Bank of Canada FI bought a new stake in shares of NewAmsterdam Pharma in the fourth quarter worth approximately $51,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of NewAmsterdam Pharma during the fourth quarter valued at approximately $80,000. KLP Kapitalforvaltning AS bought a new position in NewAmsterdam Pharma during the fourth quarter valued at approximately $154,000. Finally, Quarry LP boosted its holdings in NewAmsterdam Pharma by 2,469.2% in the third quarter. Quarry LP now owns 6,500 shares of the company’s stock worth $108,000 after purchasing an additional 6,247 shares during the last quarter. 89.89% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

NAMS has been the subject of several research reports. Needham & Company LLC decreased their target price on NewAmsterdam Pharma from $46.00 to $42.00 and set a “buy” rating for the company in a research report on Thursday, February 27th. HC Wainwright restated a “buy” rating and set a $48.00 target price on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Scotiabank upped their target price on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a research report on Thursday, February 27th. Royal Bank of Canada reissued an “outperform” rating and set a $40.00 price target on shares of NewAmsterdam Pharma in a research report on Friday, January 24th. Finally, UBS Group set a $41.00 price objective on shares of NewAmsterdam Pharma in a report on Monday, March 3rd. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $43.33.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.